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A recent major report, commissioned by the South African 
Government, examines alternative long-term scenarios for the costs 
and benefits of HIV prevention and treatment, and care for orphans 
and others affected by AIDS in South Africa.1 Not considered by the 
report is what one might call ‘treatment-centred prevention’ (TcP), by 
which we mean a combination of regular testing for HIV, immediate 
highly active antiretroviral therapy (HAART) offered to all infected 
individuals, and other proven HIV prevention methods. Such an 
approach could dramatically reduce infectiousness of HIV-positive 
people, leading to critical reductions in the rate of new infections.
The concept behind TcP, which has attracted considerable attention 
of late, has also caused much controversy.2-10 Indeed, TcP faces serious 
challenges, including the logistical and human resource constraints of the 
South African health system,11 unknown acceptability of regular testing 
and early treatment, the risk of treatment side-effects and drug resistance,12 
and the huge immediate costs of offering antiretrovirals to any HIV-
positive person, regardless of CD4 count or stage of disease.13-15
But is there really such a big difference in the ultimate costs 
between the TcP approach and current strategies where people can 
be treated only when they have sufficiently advanced disease? Few 
would dispute that infected individuals should start treatment before 
they are at substantial risk of death, but also before undue morbidity 
and associated health care costs are incurred as a result of untreated 
HIV infection. Any defensible treatment plan therefore already aims 
to offer HIV care and support to the majority of those infected, for 
the period of remaining post-treatment life expectancy – possibly 
several decades.16,17 Hence, the ultimate cost difference between 
treating people very soon after infection versus 5 or so years later, is 
then not a large proportion of the total treatment cost of TcP.
The effects of immediate versus delayed HIV treatment on the 
incidence of HIV, however, are likely to be vastly different. Whereas 
the former strategy offers suppression of the viral load after a short 
period of time – on average, half the interval between consecutive 
HIV tests – the latter only does so after several years of potential 
onward HIV transmission. Earlier initiation of HIV treatment also 
confers protection against TB, as the hazard of active TB increases 
with declining CD4 count.18-20 In people on HAART, this hazard is 
reduced by 60%.21
Mathematical model projections for scenarios of immediate versus 
delayed HAART initiation support the intuitive statements on the 
comparable costs and diverging effects of these alternative treatment 
strategies (Fig. 1). For the first 10 years of TcP, the cumulative number 
of person-years on HAART would be about double of what we expect 
under the current treatment policy. Lower HIV incidence rates 
under TcP would result in a decreasing need for HAART initiation, 
in contrast to the sustained pool of people in need of HIV treatment 
if treatment remains delayed until several years after infection (cf. 
Figs 1a, 1b). A substantially reduced HIV prevalence under TcP, in 
combination with the protective effect of HAART on TB, explains 
why TcP could have a large influence on the incidence of TB (Figs 
1c, 1d).
In conclusion: regardless of our approach to treatment, we are 
inevitably faced with the problem of funding and administering a 
treatment programme of unprecedented size, complexity and cost 
for decades to come. If the indirect costs to society of HIV-related 
morbidity and mortality are taken into account as well,22,23 deferred 
HAART initiation becomes the more expensive rather than the 
cheaper option. The important point is that the current treatment 
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Fig. 1a. Projected cumulative number of incident HIV infections.
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Fig. 1b. Projected cumulative person-years of HAART provision.
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policy does little to reduce the rate of new infections, but does 
ensure that people are sicker, and require more medical attention 
and expenditure, when they start treatment. TcP is one of the few 
credible plans to turn off the tap of new infections, providing real 
hope that we can reduce the HIV epidemic to negligible levels. The 
choice that South Africa faces is not between spending much more 
or considerably less money on HIV treatment – it is about attempting 
to eradicate HIV over the next two generations, or accepting endemic 
levels of HIV infection, quite probably for many more generations.
Fig. 1c. Measured and modelled HIV prevalence among 15 - 49-year-old in-
dividuals in South Africa. Data source: South African national HIV preva-
lence household surveys 2002, 2005, 2008.
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Fig. 1d. Estimated and projected incidence of TB. Data source: World Health 
Organization Global TB database.
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